ArticleThe oncologist2025
Real-life follow-up after discontinuation of anti-PD1 therapy for complete-response cutaneous squamous cell carcinoma in patients over 75 years of age.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMetastatic or locally advanced cutaneous squamous cell carcinomas (CSCC) affect mainly individuals over 75 years of age. Anti-PD1 therapy is the first-line treatment. Limited data are available on the continuation of immunotherapy after complete response (CR) has been achieved. MATERIALS AND
methodsWe present a retrospective monocentric study of patients over 75 years of age treated with anti-PD1 therapy for CSCC after early immunotherapy discontinuation. Patients were treated between 01/2019 and 01/2024.
resultsWe identified 44 patients over 75 years of age treated with anti-PD1 therapy, 14 of whom achieved CR, leading to the discontinuation (31%). Median age was 83.5 years. Tumor were located on the head and neck in 92.9% of cases. Median follow-up was 20 months. Median time to CR was 5 months. Discontinuation occurred 1.3 months after the CR diagnosis. One-third of the patients experienced no adverse events. Only one patient experienced grade 3 toxicity, and 10 months after discontinuation of treatment, experienced a nodal recurrence. One death occurred 8 months after CR and was unrelated to CSCC or treatment.
conclusionAnti-PD1 therapy is effective and safe in elderly patients. CR can be achieved quickly and maintained, despite early treatment discontinuation. The use of anti-PD1 therapy is therefore encouraged even in this fragile and comorbid population, with discontinuation planned as soon as a complete response is obtained to limit the duration of treatment and promote quality of life for patients. Further studies and prolonged follow-up are needed to establish guidelines regarding anti-PD1 discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.